MAGEA3 and neoplasm: To evaluate the efficiency of the candidate TCR in targeting and eliminating MAGE-A3+ tumor cells, we engineered TCR T-cells via transduction of the anti-CD3-treated PBMCs with a lentivirus containing the aforementioned anti-MAGE-A3 construct (n=7), with the vehicle-transduced cells serving as a control.